Kitasato University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tokyo Japan (2008)

Organization Overview

First Clinical Trial
2008
NCT00150670
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Centre for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University | East Hospital, Kitasato University | Kitasato University | Kitasato University East Hospital, Kanagawa, Japan | Kitasato University Hospital | Kitasato University Kitasato Institute for Life Sciences | Kitasato University Kitasato Institute Hospital | Kitasato University School of Medicine | Yuji KUMAGAI

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 2)

Behcet Syndrome (Phase 3)

Cardiovascular Diseases (Phase 4)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Hypertension (Phase 4)

Influenza, Human (Phase 2)

Influenza in Birds (Phase 2)

Kidney Diseases (Phase 4)

Prostatic Neoplasms (Phase 1)

Renal Insufficiency, Chronic (Phase 4)

Stomach Neoplasms (Phase 3)

Ulcer (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 18